Pulmonary exacerbations in cystic fibrosis

Area of Science:

• Pulmonary Medicine
• Pediatric Pulmonology
• Clinical Epidemiology

Background:

• Pulmonary exacerbations are a primary cause of morbidity in cystic fibrosis (CF).
• Decisions regarding antibiotic treatment for CF pulmonary exacerbations are complex and rely on clinical judgment.
• Objective criteria are needed to standardize treatment decisions and clinical trial outcomes.

Purpose of the Study:

• To identify clinical characteristics that predict the need for antibiotic treatment in pulmonary exacerbations among CF patients.
• To develop a model for assisting treatment decisions and serving as an outcome measure in clinical trials.

Main Methods:

• A prospective, multicenter database (Epidemiologic Study of Cystic Fibrosis) was utilized.
• Data from 11,692 patients were analyzed, comparing a 12-month baseline with a subsequent 6-month study period.
• Stepwise multiple logistic regression identified key predictive characteristics, with separate analyses for patients <6 and >=6 years old.

Main Results:

• For patients <6 years, key indicators included new crackles, increased cough, weight decline, and increased sputum production.
• For patients >=6 years, key indicators included decreased forced expiratory volume in 1 second (FEV1), increased cough, new crackles, and hemoptysis.
• The presence of three or more of these characteristics strongly correlated with treated exacerbations.

Conclusions:

• A model based on specific clinical characteristics can effectively identify CF patients requiring antibiotic treatment for pulmonary exacerbations.
• This model demonstrates reproducibility and has potential utility in clinical trials and individual patient management.
• Standardizing the identification of exacerbations can improve care consistency and research outcomes in cystic fibrosis.